FY2016 EPS Estimates for TESARO, Inc. (TSRO) Increased by Analyst

TESARO, Inc. (NASDAQ:TSRO) – Stock analysts at Leerink Swann raised their FY2016 earnings per share (EPS) estimates for TESARO in a research note issued to investors on Monday. Leerink Swann analyst S. Fernandez now anticipates that the brokerage will post earnings of ($7.50) per share for the year, up from their prior estimate of ($7.75). Leerink Swann currently has a “Outperform” rating and a $152.00 price target on the stock. Leerink Swann also issued estimates for TESARO’s Q4 2016 earnings at ($2.03) EPS, FY2017 earnings at ($6.55) EPS, FY2018 earnings at ($2.63) EPS, FY2019 earnings at $2.95 EPS and FY2020 earnings at $7.98 EPS.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($1.98) earnings per share for the quarter, missing the consensus estimate of ($1.92) by $0.06. The business had revenue of $3.73 million for the quarter, compared to the consensus estimate of $4.39 million. TESARO had a negative return on equity of 141.88% and a negative net margin of 798.68%. TESARO’s revenue was up 4187.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.66) earnings per share.

TRADEMARK VIOLATION WARNING: “FY2016 EPS Estimates for TESARO, Inc. (TSRO) Increased by Analyst” was first posted by Community Financial News and is the propert of of Community Financial News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.com-unik.info/2017/01/11/fy2016-eps-estimates-for-tesaro-inc-tsro-increased-by-analyst.html.

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Several other analysts have also recently commented on TSRO. Credit Suisse Group reiterated a “buy” rating and issued a $122.00 target price on shares of TESARO in a report on Friday, November 4th. Robert W. Baird reiterated an “outperform” rating and issued a $127.00 target price on shares of TESARO in a report on Thursday, December 22nd. Lake Street Capital reiterated a “buy” rating and issued a $150.00 target price (up from $114.00) on shares of TESARO in a report on Monday, November 7th. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $91.60 target price on shares of TESARO in a report on Wednesday, September 14th. Finally, Raymond James Financial, Inc. reiterated a “market perform” rating on shares of TESARO in a report on Friday, November 4th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $118.40.

Shares of TESARO (NASDAQ:TSRO) traded down 1.28% during trading on Wednesday, hitting $145.35. 613,526 shares of the stock traded hands. The firm’s market cap is $7.51 billion. The company has a 50-day moving average of $134.61 and a 200-day moving average of $107.12. TESARO has a 52 week low of $29.51 and a 52 week high of $153.65.

Institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of TESARO by 112.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,415 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 749 shares during the last quarter. Citizens Financial Group Inc RI purchased a new position in shares of TESARO during the third quarter worth $154,000. CenturyLink Investment Management Co purchased a new position in shares of TESARO during the third quarter worth $172,000. Pacer Advisors Inc. purchased a new position in shares of TESARO during the third quarter worth $216,000. Finally, KCG Holdings Inc. purchased a new position in shares of TESARO during the second quarter worth $228,000. 97.40% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “FY2016 EPS Estimates for TESARO, Inc. (TSRO) Increased by Analyst” was first posted by Community Financial News and is the propert of of Community Financial News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.com-unik.info/2017/01/11/fy2016-eps-estimates-for-tesaro-inc-tsro-increased-by-analyst.html.

In other news, SVP Martin H. Jr. Huber sold 327 shares of the company’s stock in a transaction that occurred on Wednesday, November 2nd. The stock was sold at an average price of $121.29, for a total transaction of $39,661.83. Following the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $223,416.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 40.50% of the company’s stock.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

5 Day Chart for NASDAQ:TSRO

What are top analysts saying about TESARO Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TESARO Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit